JP2010535825A5 - - Google Patents

Info

Publication number

JP2010535825A5

JP2010535825A5 JP2010520478A JP2010520478A JP2010535825A5 JP 2010535825 A5 JP2010535825 A5 JP 2010535825A5 JP 2010520478 A JP2010520478 A JP 2010520478A JP 2010520478 A JP2010520478 A JP 2010520478A JP 2010535825 A5 JP2010535825 A5 JP 2010535825A5

Authority

JP

Japan

Prior art keywords

multiple sclerosis

disease

composition

antibody

ivig

Prior art date

2008-08-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 claims description 139
• 201000006417 multiple sclerosis Diseases 0.000 claims description 117
• 238000000034 method Methods 0.000 claims description 104
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 103
• 150000007523 nucleic acids Chemical class 0.000 claims description 88
• 238000011282 treatment Methods 0.000 claims description 85
• 210000004027 cell Anatomy 0.000 claims description 77
• 102000039446 nucleic acids Human genes 0.000 claims description 77
• 108020004707 nucleic acids Proteins 0.000 claims description 77
• 102000004169 proteins and genes Human genes 0.000 claims description 77
• 239000000203 mixture Substances 0.000 claims description 75
• 102000019034 Chemokines Human genes 0.000 claims description 67
• 108010012236 Chemokines Proteins 0.000 claims description 67
• 230000014509 gene expression Effects 0.000 claims description 67
• 150000001875 compounds Chemical class 0.000 claims description 61
• 108060003951 Immunoglobulin Proteins 0.000 claims description 50
• 102000018358 immunoglobulin Human genes 0.000 claims description 50
• 230000000694 effects Effects 0.000 claims description 47
• 208000024827 Alzheimer disease Diseases 0.000 claims description 42
• 208000018737 Parkinson disease Diseases 0.000 claims description 42
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 34
• 239000000523 sample Substances 0.000 claims description 33
• 239000003550 marker Substances 0.000 claims description 31
• 108020004459 Small interfering RNA Proteins 0.000 claims description 23
• 239000003153 chemical reaction reagent Substances 0.000 claims description 20
• 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 claims description 19
• 102000009410 Chemokine receptor Human genes 0.000 claims description 18
• 108050000299 Chemokine receptor Proteins 0.000 claims description 18
• 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 17
• 108090000994 Catalytic RNA Proteins 0.000 claims description 17
• 102000053642 Catalytic RNA Human genes 0.000 claims description 17
• 102100035298 Cytokine SCM-1 beta Human genes 0.000 claims description 17
• 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 17
• 108091092562 ribozyme Proteins 0.000 claims description 17
• 210000004369 blood Anatomy 0.000 claims description 16
• 239000008280 blood Substances 0.000 claims description 16
• 238000001990 intravenous administration Methods 0.000 claims description 16
• 108091034117 Oligonucleotide Proteins 0.000 claims description 14
• 238000004393 prognosis Methods 0.000 claims description 13
• 230000007423 decrease Effects 0.000 claims description 11
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
• 102000005962 receptors Human genes 0.000 claims description 10
• 108020003175 receptors Proteins 0.000 claims description 10
• 230000004913 activation Effects 0.000 claims description 9
• 230000002018 overexpression Effects 0.000 claims description 9
• 230000009452 underexpressoin Effects 0.000 claims description 9
• 239000012472 biological sample Substances 0.000 claims description 6
• 230000005754 cellular signaling Effects 0.000 claims description 5
• 229910052799 carbon Inorganic materials 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 150000003384 small molecules Chemical class 0.000 claims description 3
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 2
• 102100023702 C-C motif chemokine 13 Human genes 0.000 claims 3
• 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims 3
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 1
• 230000006806 disease prevention Effects 0.000 claims 1
• 230000000415 inactivating effect Effects 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 description 74
• 241000282414 Homo sapiens Species 0.000 description 54
• 150000001413 amino acids Chemical class 0.000 description 50
• 235000001014 amino acid Nutrition 0.000 description 38
• 229940024606 amino acid Drugs 0.000 description 38
• 238000009472 formulation Methods 0.000 description 32
• 108090000765 processed proteins & peptides Chemical group 0.000 description 31
• 239000000090 biomarker Substances 0.000 description 28
• 238000003556 assay Methods 0.000 description 27
• 102000004196 processed proteins & peptides Human genes 0.000 description 27
• 229920001184 polypeptide Chemical group 0.000 description 24
• 238000012360 testing method Methods 0.000 description 24
• 210000004556 brain Anatomy 0.000 description 23
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 22
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 22
• 239000000126 substance Substances 0.000 description 22
• 102000016948 Chemokine CXCL5 Human genes 0.000 description 19
• 108010014421 Chemokine CXCL5 Proteins 0.000 description 19
• 238000009396 hybridization Methods 0.000 description 19
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
• 238000004458 analytical method Methods 0.000 description 18
• 108020004999 messenger RNA Proteins 0.000 description 17
• 230000004048 modification Effects 0.000 description 17
• 238000012986 modification Methods 0.000 description 17
• 230000002093 peripheral effect Effects 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 238000003018 immunoassay Methods 0.000 description 16
• 125000003729 nucleotide group Chemical group 0.000 description 16
• 238000002560 therapeutic procedure Methods 0.000 description 16
• 230000027455 binding Effects 0.000 description 15
• 238000009739 binding Methods 0.000 description 15
• 239000012634 fragment Substances 0.000 description 15
• 239000002773 nucleotide Substances 0.000 description 15
• 210000004248 oligodendroglia Anatomy 0.000 description 15
• 230000001105 regulatory effect Effects 0.000 description 15
• 229940072221 immunoglobulins Drugs 0.000 description 14
• 239000003446 ligand Substances 0.000 description 14
• 238000002595 magnetic resonance imaging Methods 0.000 description 13
• 239000003814 drug Substances 0.000 description 12
• 102000040430 polynucleotide Human genes 0.000 description 12
• 108091033319 polynucleotide Proteins 0.000 description 12
• 239000002157 polynucleotide Substances 0.000 description 12
• 239000013598 vector Substances 0.000 description 12
• 108020004705 Codon Proteins 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 10
• 238000004422 calculation algorithm Methods 0.000 description 10
• 210000003169 central nervous system Anatomy 0.000 description 10
• 230000000295 complement effect Effects 0.000 description 10
• 235000018417 cysteine Nutrition 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 238000003752 polymerase chain reaction Methods 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• -1 CCL13 Proteins 0.000 description 9
• 108091028043 Nucleic acid sequence Proteins 0.000 description 9
• 239000000427 antigen Substances 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 210000004408 hybridoma Anatomy 0.000 description 9
• 230000010534 mechanism of action Effects 0.000 description 9
• 230000035897 transcription Effects 0.000 description 9
• 238000013518 transcription Methods 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 101001135402 Homo sapiens Prostaglandin-H2 D-isomerase Proteins 0.000 description 8
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 8
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 8
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
• 230000000692 anti-sense effect Effects 0.000 description 8
• 230000003902 lesion Effects 0.000 description 8
• 238000002493 microarray Methods 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 241000124008 Mammalia Species 0.000 description 7
• 108091005461 Nucleic proteins Proteins 0.000 description 7
• 239000012190 activator Substances 0.000 description 7
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 238000003753 real-time PCR Methods 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 6
• 208000016192 Demyelinating disease Diseases 0.000 description 6
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• 101000762243 Homo sapiens Cadherin-13 Proteins 0.000 description 6
• 101000824299 Homo sapiens Protocadherin Fat 2 Proteins 0.000 description 6
• 102000002452 NPR3 Human genes 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 210000001218 blood-brain barrier Anatomy 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 229940124452 immunizing agent Drugs 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 238000010253 intravenous injection Methods 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 238000010208 microarray analysis Methods 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 238000003757 reverse transcription PCR Methods 0.000 description 6
• 102000004046 Caspase-2 Human genes 0.000 description 5
• 108090000552 Caspase-2 Proteins 0.000 description 5
• 206010012305 Demyelination Diseases 0.000 description 5
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
• 102000003815 Interleukin-11 Human genes 0.000 description 5
• 108090000177 Interleukin-11 Proteins 0.000 description 5
• 108091093037 Peptide nucleic acid Proteins 0.000 description 5
• 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 5
• 101710195838 Prostaglandin E2 receptor EP4 subtype Proteins 0.000 description 5
• 101710161469 SH3 domain-binding protein 4 Proteins 0.000 description 5
• 102100028409 SH3 domain-binding protein 4 Human genes 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000001186 cumulative effect Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 210000002865 immune cell Anatomy 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 229940074383 interleukin-11 Drugs 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 230000000750 progressive effect Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 108700020463 BRCA1 Proteins 0.000 description 4
• 102000036365 BRCA1 Human genes 0.000 description 4
• 102000001902 CC Chemokines Human genes 0.000 description 4
• 108010040471 CC Chemokines Proteins 0.000 description 4
• 108050006947 CXC Chemokine Proteins 0.000 description 4
• 102000019388 CXC chemokine Human genes 0.000 description 4
• 102100024154 Cadherin-13 Human genes 0.000 description 4
• 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 4
• 206010010904 Convulsion Diseases 0.000 description 4
• 229910052688 Gadolinium Inorganic materials 0.000 description 4
• 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 4
• 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 4
• 101001056724 Homo sapiens Intersectin-1 Proteins 0.000 description 4
• 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 description 4
• 101000989639 Homo sapiens Major facilitator superfamily domain-containing protein 12 Proteins 0.000 description 4
• 101000966843 Homo sapiens Myotubularin-related protein 7 Proteins 0.000 description 4
• 101001128581 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 Proteins 0.000 description 4
• 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 description 4
• 101001095308 Homo sapiens Periostin Proteins 0.000 description 4
• 101000730493 Homo sapiens Phosphatidylinositol-glycan-specific phospholipase D Proteins 0.000 description 4
• 101000987488 Homo sapiens Protein pelota homolog Proteins 0.000 description 4
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
• 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 description 4
• 102100029281 Major facilitator superfamily domain-containing protein 12 Human genes 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 4
• 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 4
• 102100032199 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 Human genes 0.000 description 4
• 102100024761 Neutrophil defensin 3 Human genes 0.000 description 4
• 101710163270 Nuclease Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 102100032538 Phosphatidylinositol-glycan-specific phospholipase D Human genes 0.000 description 4
• 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 description 4
• 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 102100022093 Protocadherin Fat 2 Human genes 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 230000009798 acute exacerbation Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 229940049706 benzodiazepine Drugs 0.000 description 4
• 150000001557 benzodiazepines Chemical class 0.000 description 4
• 208000025698 brain inflammatory disease Diseases 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 230000022131 cell cycle Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 239000003593 chromogenic compound Substances 0.000 description 4
• 150000001945 cysteines Chemical class 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 230000029087 digestion Effects 0.000 description 4
• 201000010099 disease Diseases 0.000 description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 238000001962 electrophoresis Methods 0.000 description 4
• 206010014599 encephalitis Diseases 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 239000007850 fluorescent dye Substances 0.000 description 4
• 238000005194 fractionation Methods 0.000 description 4
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 102000056002 human PTGDS Human genes 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 229930182817 methionine Natural products 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 230000008506 pathogenesis Effects 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 108050005711 C Chemokine Proteins 0.000 description 3
• 102000017483 C chemokine Human genes 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 108090000526 Papain Proteins 0.000 description 3
• 102000057297 Pepsin A Human genes 0.000 description 3
• 108090000284 Pepsin A Proteins 0.000 description 3
• 238000011529 RT qPCR Methods 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 208000034189 Sclerosis Diseases 0.000 description 3
• 241000251131 Sphyrna Species 0.000 description 3
• 102000014384 Type C Phospholipases Human genes 0.000 description 3
• 108010079194 Type C Phospholipases Proteins 0.000 description 3
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 238000000137 annealing Methods 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• 230000003376 axonal effect Effects 0.000 description 3
• 230000003385 bacteriostatic effect Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 210000005220 cytoplasmic tail Anatomy 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 150000001982 diacylglycerols Chemical class 0.000 description 3
• JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 3
• 239000005090 green fluorescent protein Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 230000003832 immune regulation Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000004255 ion exchange chromatography Methods 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 238000010606 normalization Methods 0.000 description 3
• 238000007899 nucleic acid hybridization Methods 0.000 description 3
• 229940055729 papain Drugs 0.000 description 3
• 235000019834 papain Nutrition 0.000 description 3
• 239000013610 patient sample Substances 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 210000004976 peripheral blood cell Anatomy 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 235000019833 protease Nutrition 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
• 239000012096 transfection reagent Substances 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 2
• 208000012639 Balance disease Diseases 0.000 description 2
• 102100032440 Beta-1,3-galactosyltransferase 2 Human genes 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 2
• 102000003930 C-Type Lectins Human genes 0.000 description 2
• 108090000342 C-Type Lectins Proteins 0.000 description 2
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
• 108010069514 Cyclic Peptides Proteins 0.000 description 2
• 102000001189 Cyclic Peptides Human genes 0.000 description 2
• 108010017222 Cyclin-Dependent Kinase Inhibitor p57 Proteins 0.000 description 2
• 102000004480 Cyclin-Dependent Kinase Inhibitor p57 Human genes 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 101710088194 Dehydrogenase Proteins 0.000 description 2
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
• 108010016626 Dipeptides Proteins 0.000 description 2
• 208000003164 Diplopia Diseases 0.000 description 2
• 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 2
• 102100029712 E3 ubiquitin-protein ligase TRIM58 Human genes 0.000 description 2
• 102000012545 EGF-like domains Human genes 0.000 description 2
• 108050002150 EGF-like domains Proteins 0.000 description 2
• 101150059401 EGR2 gene Proteins 0.000 description 2
• 108700039887 Essential Genes Proteins 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 102000030782 GTP binding Human genes 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
• 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 2
• 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 2
• 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 2
• 101000798387 Homo sapiens Beta-1,3-galactosyltransferase 2 Proteins 0.000 description 2
• 101000934870 Homo sapiens Breast cancer type 1 susceptibility protein Proteins 0.000 description 2
• 101000867612 Homo sapiens Caspase-2 Proteins 0.000 description 2
• 101000944365 Homo sapiens Cyclin-dependent kinase inhibitor 1C Proteins 0.000 description 2
• 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 2
• 101000795365 Homo sapiens E3 ubiquitin-protein ligase TRIM58 Proteins 0.000 description 2
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
• 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 2
• 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 2
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
• 101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 description 2
• 101001117509 Homo sapiens Prostaglandin E2 receptor EP4 subtype Proteins 0.000 description 2
• 101000743825 Homo sapiens Protein zwilch homolog Proteins 0.000 description 2
• 101000632535 Homo sapiens SH3 domain-binding protein 4 Proteins 0.000 description 2
• 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 description 2
• 101000662690 Homo sapiens Trafficking protein particle complex subunit 10 Proteins 0.000 description 2
• 101000801314 Homo sapiens Transmembrane protein 47 Proteins 0.000 description 2
• 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 2
• 101000964741 Homo sapiens Zinc finger protein 711 Proteins 0.000 description 2
• 101000802405 Homo sapiens Zinc finger protein 771 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 101710203526 Integrase Proteins 0.000 description 2
• 102100025494 Intersectin-1 Human genes 0.000 description 2
• 108010043610 KIR Receptors Proteins 0.000 description 2
• 102000002698 KIR Receptors Human genes 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
• 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
• 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• 102100040601 Myotubularin-related protein 7 Human genes 0.000 description 2
• 101150066297 NPR3 gene Proteins 0.000 description 2
• 208000003435 Optic Neuritis Diseases 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 101150054854 POU1F1 gene Proteins 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 102100037765 Periostin Human genes 0.000 description 2
• 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 241000276498 Pollachius virens Species 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102100028485 Protein pelota homolog Human genes 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 108091030071 RNAI Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102100026159 Tomoregulin-1 Human genes 0.000 description 2
• 101710106896 Transmembrane protein 47 Proteins 0.000 description 2
• 102100033526 Transmembrane protein 47 Human genes 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108010046334 Urease Proteins 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 102100040724 Zinc finger protein 711 Human genes 0.000 description 2
• 101710182141 Zinc finger protein 711 Proteins 0.000 description 2
• 102100034967 Zinc finger protein 771 Human genes 0.000 description 2
• 101710182376 Zinc finger protein 771 Proteins 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000030570 cellular localization Effects 0.000 description 2
• 210000002230 centromere Anatomy 0.000 description 2
• 230000035605 chemotaxis Effects 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 239000002872 contrast media Substances 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000003210 demyelinating effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 208000029444 double vision Diseases 0.000 description 2
• 238000009509 drug development Methods 0.000 description 2
• 230000000763 evoking effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 102000046101 human AFP Human genes 0.000 description 2
• 102000052835 human CASP2 Human genes 0.000 description 2
• 102000049771 human CDKN1C Human genes 0.000 description 2
• 102000046622 human FAT2 Human genes 0.000 description 2
• 102000049885 human IL11 Human genes 0.000 description 2
• 102000050339 human ITSN1 Human genes 0.000 description 2
• 102000048890 human MAP4K2 Human genes 0.000 description 2
• 102000053042 human MTMR7 Human genes 0.000 description 2
• 102000048431 human POSTN Human genes 0.000 description 2
• 102000052798 human PTGER4 Human genes 0.000 description 2
• 102000046998 human SH3BP4 Human genes 0.000 description 2
• 102000048045 human TMEM47 Human genes 0.000 description 2
• 102000048498 human TRAPPC10 Human genes 0.000 description 2
• 102000047232 human XCL2 Human genes 0.000 description 2
• 102000058001 human ZNF711 Human genes 0.000 description 2
• 102000044782 human Zwilch Human genes 0.000 description 2
• 210000003917 human chromosome Anatomy 0.000 description 2
• 102000056287 human pelo Human genes 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000000984 immunochemical effect Effects 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 230000004957 immunoregulator effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011503 in vivo imaging Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 230000002045 lasting effect Effects 0.000 description 2
• 150000002611 lead compounds Chemical class 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 210000000274 microglia Anatomy 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 230000023105 myelination Effects 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 210000004498 neuroglial cell Anatomy 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 210000000963 osteoblast Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 150000004713 phosphodiesters Chemical class 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000001124 posttranscriptional effect Effects 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000004445 quantitative analysis Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 150000003839 salts Chemical group 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 101150056399 slc20a1 gene Proteins 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000011272 standard treatment Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 230000009747 swallowing Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
• SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
• 238000007817 turbidimetric assay Methods 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
• KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
• WNIBBTQHSPZYMK-UHFFFAOYSA-N 3-bromo-2-methylphenol;urea Chemical compound NC(N)=O.CC1=C(O)C=CC=C1Br WNIBBTQHSPZYMK-UHFFFAOYSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
• 102100028699 C-type lectin domain family 4 member E Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
• 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
• 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
• 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 108010093099 Endoribonucleases Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000766921 Homo sapiens C-type lectin domain family 4 member E Proteins 0.000 description 1
• 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
• 101001035935 Homo sapiens Intracellular hyaluronan-binding protein 4 Proteins 0.000 description 1
• 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
• 101000613969 Homo sapiens Origin recognition complex subunit 1 Proteins 0.000 description 1
• 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010041012 Integrin alpha4 Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100039227 Intracellular hyaluronan-binding protein 4 Human genes 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 102100035304 Lymphotactin Human genes 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
• 101000824301 Mus musculus Protocadherin Fat 2 Proteins 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 102100040591 Origin recognition complex subunit 1 Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 238000002944 PCR assay Methods 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 102000004211 Platelet factor 4 Human genes 0.000 description 1
• 108090000778 Platelet factor 4 Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 210000000447 Th1 cell Anatomy 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 238000001790 Welch's t-test Methods 0.000 description 1
• 102000043366 Wnt-5a Human genes 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 101100187345 Xenopus laevis noto gene Proteins 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 208000030137 articulation disease Diseases 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 208000035556 autoimmune disorder of central nervous system Diseases 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000003796 beauty Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000004656 cell transport Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000013626 chemical specie Substances 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 239000012504 chromatography matrix Substances 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000022371 chronic pain syndrome Diseases 0.000 description 1
• 231100000876 cognitive deterioration Toxicity 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000002247 constant time method Methods 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000011257 definitive treatment Methods 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 238000004401 flow injection analysis Methods 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
• 229940009600 gammagard Drugs 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 239000011544 gradient gel Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 238000012203 high throughput assay Methods 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 102000056496 human CXCL5 Human genes 0.000 description 1
• 150000001469 hydantoins Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 229940124625 intravenous corticosteroids Drugs 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000002075 inversion recovery Methods 0.000 description 1
• XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
• 238000000670 ligand binding assay Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 230000005415 magnetization Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 239000013586 microbial product Substances 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 206010029864 nystagmus Diseases 0.000 description 1
• 238000002966 oligonucleotide array Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000000123 paper Substances 0.000 description 1
• 238000009928 pasteurization Methods 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 229960000380 propiolactone Drugs 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 238000012175 pyrosequencing Methods 0.000 description 1
• 150000003235 pyrrolidines Chemical class 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000035456 regulation of T cell proliferation Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 230000015227 regulation of liquid surface tension Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 230000027756 respiratory electron transport chain Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 238000007480 sanger sequencing Methods 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
• 230000011218 segmentation Effects 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000012488 skeletal system development Effects 0.000 description 1
• YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
• 230000003238 somatosensory effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 238000006277 sulfonation reaction Methods 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 150000003505 terpenes Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1